FibroGen, AstraZeneca Up After Roxadustat Data

Date : 11/08/2019 @ 8:19PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7174.0  -80.0 (-1.10%) @ 8:48AM

FibroGen, AstraZeneca Up After Roxadustat Data

AstraZeneca (NYSE:AZN)
Historical Stock Chart

1 Month : From Oct 2019 to Nov 2019

Click Here for more AstraZeneca Charts.

By Michael Dabaie

 

AstraZeneca PLC (AZN) and FibroGen Inc. (FGEN) said roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease.

FibroGen shares turned positive after trading down earlier in the session, recently up 9.5%, to $41.56. AstraZeneca ADRs also turned positive, recently up 0.6%, at $47.09.

In non dialysis-dependent patients receiving roxadustat, the risk of major adverse CV events, defined as all-cause mortality, stroke and myocardial infarction, MACE+, which is defined as MACE, unstable angina requiring hospitalization and congestive heart failure requiring hospitalization, and all-cause mortality was comparable to placebo, the companies said.

In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 08, 2019 15:04 ET (20:04 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.